Roselinde Boyne, APRN
Family · Charlotte, MINPI 1669887881
Payments from drug & device makers
Across 140 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$477
- Boehringer Ingelheim$290
- AbbVie$277
- Pfizer$225
- GSK$194
- Takeda Pharmaceuticals U.S.A., Inc.$147
- plus $977 from 23 others
What the payments were for
- Food & beverage$2,586100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 26 | $477 |
| Boehringer Ingelheim | 12 | $290 |
| AbbVie | 16 | $277 |
| Pfizer | 13 | $225 |
| GSK | 10 | $194 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $147 |
| AstraZeneca | 10 | $144 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $78 |
| Sumitomo Pharma America, Inc. | 4 | $76 |
| Exact Sciences | 4 | $75 |
| Lilly USA, LLC | 4 | $60 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| Amgen | 3 | $53 |
| Merck | 2 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $47 |
| Viatris Specialty LLC | 2 | $47 |
| Bayer | 3 | $46 |
| Dexcom, Inc. | 3 | $41 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Averitas Pharma Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Halozyme Inc | 1 | $15 |
| Phadia US Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$2,586 in reported general payments places this provider in the 85th percentile of 3,657 family providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 125 | $196,886 |
| EliquisApixaban | 114 | $116,316 |
| TrulicityDulaglutide | 59 | $72,688 |
| JardianceEmpagliflozin | 42 | $58,475 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $43,649 |
| FarxigaDapagliflozin Propanediol | 33 | $39,240 |
| Breo ElliptaFluticasone/Vilanterol | 50 | $25,997 |
| MyrbetriqMirabegron | 19 | $21,651 |
| InvokanaCanagliflozin | 15 | $19,013 |
| XareltoRivaroxaban | 20 | $17,667 |
| MounjaroTirzepatide | 11 | $15,260 |
| Spiriva RespimatTiotropium Bromide | 16 | $15,137 |
| TrintellixVortioxetine Hydrobromide | 14 | $11,411 |
| Bydureon BciseExenatide Microspheres | 13 | $10,115 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $8,901 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $477 | $196,886125 claims |
| PfizerEliquis, Premarin | $225 | $124,175131 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $60 | $87,94870 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $194 | $78,547114 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $290 | $73,61258 claims |
| AstraZenecaFarxiga, Symbicort | $144 | $44,90351 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $147 | $11,41114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,657 family providers in Michigan.
Other family in Charlotte
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.